Status:
COMPLETED
A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease
Lead Sponsor:
University of Dundee
Conditions:
COPD
Eligibility:
All Genders
50-90 years
Phase:
PHASE4
Brief Summary
Chronic Obstructive Pulmonary Disease (COPD) is a major worldwide problem.Steroids inhalers are now an established treatment for COPD. Inhaled steroids can have a number of bad effects including suppr...
Eligibility Criteria
Inclusion
- Current or ex-smokers
- Aged over 50years
- FEV1/FVC ratio \<0.7
- FEV1\<80% predicted
- Improvement in FEV1 following short acting beta-agonist not greater than 15% and 200ml.
Exclusion
- Diagnosis of asthma, bronchiectasis or ABPA
- Inability to perform study procedures or give informed consent
- Known sensitivity to trial medications
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00995475
Start Date
October 1 2006
End Date
November 1 2008
Last Update
May 19 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.